



(51) International Patent Classification:

A61B 6/00 (2006.01) A61M 5/00 (2006.01)
A61B 6/03 (2006.01) A61K 49/04 (2006.01)

(21) International Application Number:

PCT/EP2015/078737

(22) International Filing Date:

4 December 2015 (04.12.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/134,639 18 March 2015 (18.03.2015) US
15166519.7 6 May 2015 (06.05.2015) EP

(71) Applicant: **KONINKLIJKE PHILIPS N.V.** [NL/NL];
High Tech Campus 5, 5656 AE Eindhoven (NL).

(72) Inventors: **HAASE, Christian**; c/o High Tech Campus 5,
5656 AE Eindhoven (NL). **SCHÄFER, Dirk**; c/o High
Tech Campus 5, 5656 AE Eindhoven (NL). **HANSIS,
Eberhard Sebastian**; c/o High Tech Campus 5, 5656 AE
Eindhoven (NL). **KLINDER, Tobias**; c/o High Tech Cam-

pus 5, 5656 AE Eindhoven (NL). **GRASS, Michael**; c/o
High Tech Campus 5, 5656 AE Eindhoven (NL). **LIN,
Ming De**; c/o High Tech Campus 5, 5656 AE Eindhoven
(NL).

(74) Agents: **VERSTEEG, Dennis John** et al.; High Tech
Campus 5, 5656 AE Eindhoven (NL).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,

[Continued on next page]

(54) Title: DRUG CONCENTRATION DETERMINATION AFTER TRANSARTERIAL CHEMOEMBOLIZATION WITH DIFFERENT SIZED DRUG-ELUTING MICROSPHERE BEADS




FIG. 1

(57) Abstract: The present invention is directed towards a system and method for transarterial chemoembolization using differently sized drug-eluting microsphere beads filled with drugs and determining a delivered drug concentration using an imaging system.

WO 2016/146214 A1

TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, **Published:**
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, — *with international search report (Art. 21(3))*
LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Drug concentration determination after transarterial chemoembolization with different sized drug-eluting microsphere beads

FIELD OF THE INVENTION

The present invention generally relates to a system for a transarterial chemoembolization (TACE) of a region of interest comprising a tumor, a method for determining a delivered drug dose concentration in a region of interest comprising a tumor, a system for determining a drug concentration in a region of interest comprising a tumor after a transarterial TACE procedure, a computer program product for determining a drug concentration in a region of interest comprising a tumor after a transarterial TACE procedure and a TACE method.

10 BACKGROUND OF THE INVENTION

Liver cancer is one of the most common cancers worldwide. Treatment options are limited and clinical outcomes are generally poor with a median survival rate of less than one year. Given the fact that liver cancer (primary and metastatic) is primarily supplied by the hepatic artery and is generally confined to the liver, drug delivery directly into the hepatic artery has been shown to be effective. Transarterial chemoembolization (TACE) is an x-ray image guided, interventional oncology procedure in which chemotherapeutic drug is delivered from a catheter in the hepatic artery.

There has been a shift in chemotherapeutic drug delivery system from conventional lipiodol (cTACE) to drug-eluting microsphere beads (DEB-TACE). Drug-eluting microsphere beads (DEBs) are small beads with a shell and a core which may be loaded with a drug, such as chemotherapeutic agents, or other materials and which are capable of delivering the load in a reproducible manner to a region of interest that leads to lower levels of chemotherapy in plasma (less systemic exposure) and enhanced efficacy at the tumor site (more tumor kill).

An issue with TACE procedures is that it is very difficult to determine whether the intended drug dose actually reached the tumor. It is well known in chemotherapy medicine that a sufficient drug dose concentration is needed for tumor kill. With DEB-TACE some improvements were made regarding this issue. Since DEBs are usually radio-lucent, in

current clinical practice soluble x-ray contrast agent is mixed with DEBs to provide a surrogate marker of DEB deposition. However, it is known that the two materials can separate during delivery and thus provide false information about final DEB deposition location. As such, a new kind of DEB was developed that is inherently radio-opaque and thus provides direct visualization of bead deposition. In this case radio opacity in the target region is directly related to drug dose.

Over the years, the DEB's sizes have become smaller, in general from 100-300 microns to 75-150 microns in diameter. This smaller size allows for better tumor penetration. However, there are two limitations: smaller beads carry a smaller drug payload, and smaller beads are unable to embolize larger-sized tumor feeding vessels.

Also, it is known that the tumor core has a very different microenvironment than the tumor rim and different drugs are needed for each. With TACE procedures, including DEB-TACE, it is difficult to target and address both the core and rim effectively.

It would be highly desirable if a DEB-TACE method could target all areas in and around the tumor effectively with a reliable indication of drug delivery to each area.

SUMMARY OF THE INVENTION

Embodiments according to the present invention are directed to a system for a transarterial chemoembolization (TACE) of a region of interest comprising a tumor with an injector and an imaging system. The injector is arranged to introduce into the region of interest first drug-eluting microsphere beads containing at least a first drug and a first contrast agent and to introduce into the region of interest second drug-eluting microsphere beads containing at least a second drug and a second contrast agent. The imaging system is arranged to obtain a first image data set of the region of interest with at least a first x-ray radiation energy and a second image data set of the region of interest with at least a second x-ray radiation energy.

In a preferred embodiment the system further comprises a concentration determiner arranged to determine a first drug concentration from the first image data set and a second drug concentration from the second image data set.

In another preferred embodiment of the system the imaging system is a spectral computed tomography imaging system, preferably a spectral computed tomography system that is arranged to simultaneously obtain the first image data and second image data.

In another preferred embodiment of the system the first drug-eluting microsphere beads have a size such that they can not penetrate into tumor core vessels, and

the second drug-eluting microsphere beads have a size such that they can penetrate into tumor core vessels.

In another preferred embodiment of the system the first drug is different from the second drug and/or wherein the first contrast agent is different from the second contrast agent.

In another preferred embodiment of the system the at least first x-ray radiation energy corresponds to a K-absorption edge of the first contrast agent and the at least second x-ray radiation energy corresponds to a K-absorption edge of the second contrast agent.

A further embodiment of the present invention is directed towards a method for determining a delivered drug dose concentration in a region of interest comprising a tumor, comprising the steps of obtaining a first image data set by imaging the region of interest with an x-ray imaging device operating at at least a first x-ray radiation energy; determining, from the first image data set, a first drug concentration delivered to the region of interest by first drug-eluting microsphere beads containing at least a first drug and a first contrast agent; obtaining a second image data set by imaging the region of interest with an x-ray imaging device operating at at least a second x-ray radiation energy; determining, from the second image data set, a second drug concentration delivered to the region of interest by second drug-eluting microsphere beads containing at least a second drug and a second contrast agent, wherein the first drug-eluting microsphere beads have a larger diameter than the second drug-eluting microsphere beads.

Other embodiments of the present invention are directed towards Computer program product for determining a drug concentration in a tumor after a transarterial chemoembolization procedure in which at least a first drug and a second drug were delivered to the region of interest and a transarterial chemoembolization procedure.

Still further aspects and embodiments of the present invention will be appreciated by those of ordinary skill in the art upon reading and understanding the following detailed description. Numerous additional advantages and benefits will become apparent to those of ordinary skill in the art upon reading the following detailed description of preferred embodiments.

BRIEF DESCRIPTION OF THE DRAWINGS

The present invention is illustrated by drawings of which

Fig. 1 shows a schematic representation of a system for transarterial chemoembolization according to the present invention.

Fig. 2 shows a schematic representation of two differently sized drug-eluting microsphere beads.

Fig. 3 shows a schematic representation of arteries in a region of interest to which two differently sized DEBs were administered.

5 Fig. 4 shows a simulated depiction of a CT reconstruction of a liver area in a patient with an overlaid illustration of a size selective bead concentration.

Fig. 5 shows a block diagram of a TACE procedure according to the present invention (5A) and a subsequent method for determining a delivered drug dose to a region of interest (5B).

10 Fig. 6 shows a schematic depiction of a kit-of-parts according to the present invention.

The invention may take form in various components and arrangements of components, and in various process operations and arrangements of process operations. The drawings are only for the purpose of illustrating preferred embodiments and are not to be construed as limiting the invention. To better visualize certain features may be omitted or dimensions may be not be according to scale.

15

DETAILED DESCRIPTION OF EMBODIMENTS

The invention will be illustrated by using spectral CT imaging, but another suitable multi-energy imaging device or other imaging device with which it is possible to discriminate between two materials could also be used. Furthermore, the present invention is directed to treatment of liver cancer, but the invention is also easily adaptable to other types of cancer and even to local drug treatment of other diseases.

20

Figure 1 depicts a schematic representation of a system for transarterial chemoembolization 10 with two main components: an imaging system 1 and an injecting device 7.

25

In this example, the imaging system 1 is a computed tomography imaging system in which x-ray radiation is emitted in a radiation beam 6 from a source 4 towards a detector 5. Both are mounted opposite each other in a gantry 2, which is rotatable around an examination area. During an imaging procedure a subject, such as a patient, is placed on support 3 and translated through the examination region and the radiation beam 6 while the gantry 2 rotates around the subject to obtain image data of the subject that may be reconstructed to two-dimensional or three-dimensional images.

30

This invention will be particularly explained using spectral CT (sometimes also referred to as dual source CT) as an example. In spectral CT x-ray radiation with different energies are detected and processed. This may be achieved by adapting the source to emit different wavelengths simultaneously or sequentially (e.g. in kVp switching x-ray sources) or by adapting the detector to detect different individual parts of an emitted wavelength spectrum. Different information may be derived from information obtained from high-energy x-ray radiation and low-energy x-ray radiation. For instance, materials may be distinguished from each other since different materials attenuate low and high energy radiation differently.

An often used imaging method in spectral (and conventional) CT imaging is k-edge imaging, usually of contrast agent materials. Due to the photoelectric absorptions of photons in atoms of an imaged material, such as a contrast agent, a sudden, non-linear increase in the attenuation coefficient of photons at an energy just above the binding energy of the K-shell electron occurs. This sudden increase is called the k-edge, which lies at different energies for different materials and therefore it can be separately detected by imaging with different radiation energies, such as in spectral CT imaging. And, as such, it is possible to identify different materials in a single imaging procedure.

Figure 1 also shows a schematic depiction of an injecting device 7, which is drawn in a very basic form which only depicts examples of basic elements that could be part of such an injector. In this embodiment the injector 7 comprises a first DEB reservoir 71 and a second DEB reservoir 72, which both are connected to injector 73. The injector 73 may for instance be a catheter or a syringe to introduce the DEBs 81, 82 into a blood vessel, usually near the region of interest. According to the present invention the first DEB reservoir 71 is to be loaded for use with first DEBs and the second DEB reservoir is loaded with differently sized second DEBs. The skilled person would understand that the injector 73 can have many different designs and also that the DEB reservoirs 71, 72 can be connected to the injector in multiple manners. For instance, the first and second DEB reservoirs 71, 72 may be combined into one reservoir if the differently sized DEBs 81,82 are already premixed. The injecting device 7 is preferably placed close to the imaging system 1, but could also be placed away from the imaging system 1, or even in a separate room.

Figure 2 shows schematic depictions of two differently sized DEBs 81, 82. DEBs are available in various sizes, usually ranging between 50 and 1000 microns. Both DEBs 81,82 comprise of a shell 811, 821 fully surrounding a central loading cavity 812, 822. The shell 811, 821 is preferably made of a biodegradable material, such as a biodegradable

polymer, for instance a polyvinyl alcohol hydrogel. Shell thickness may vary for different DEB types and sizes. The central loading cavity 812, 822 is filled with a drug, such as for instance doxorubicin, which is often used in TACE procedures (doxorubicin DEBs are usually referred to in the trade as DEBDOX). The central loading cavity 812, 822 is also
5 filled with a contrast agent which facilitates proper imaging of the beads in an imaging procedure, for instance contrast agents based on Iodine, Gadolinium or other substances known to the skilled person. The contrast agent preferably has a k-edge that is detectable by spectral CT imaging energies. The DEBs are introduced into a patient's bloodstream and delivered to a tissue of interest, where the drug is slowly released from the DEBs 81, 82.

10 As mentioned in the introduction, a size of the DEB determines the maximum drug load and which vessels can be effectively embolized. In general, larger sized DEBs can carry a higher drug load, but cannot embolize smaller vessels, particularly those inside tumors. Smaller sized DEBs can embolize smaller vessels, but carry a lower drug load and cannot effectively embolize larger vessels, such as tumor feeding vessels.

15 An insight that lies at the basis of many aspects of this invention is that a mixture, or a subsequent administration, of differently sized DEBs 81, 82 introduced to a patient overcomes these drawbacks. This is illustrated schematically in Figure 3. This figure shows part of a blood vessel system of a patient including a feeding vessel 91 to a tumor, for instance an hepatic artery leading to a liver tumor. At a tumor rim 92 the feeding vessel 91
20 splits up into many smaller tumor core vessels 93. In this embodiment two differently sized DEBs were administered to the patient: large DEBs 81 with an exemplary diameter of around 300 microns and small DEBs 82 with an exemplary diameter of 75 microns. DEBs with other diameters and a larger number of differently sized DEBs are of course also possible, depending on the different vessel sizes and can be chosen by a physician on a case-by-case
25 basis. The small DEBs 82 are able to embolize the small tumor core vessels 93 to release the drug there locally. While small DEBs 82 are also present in the feeding vessel 91, they do not effectively embolize said feeding vessel 91. The large DEBs however do embolize the feeding vessel 91 very well. The large DEBs 81 are too large to enter the tumor core vessels 93 and will, in this embodiment, not pass beyond the tumor rim 92. A good embolization of
30 all relevant vessels in around the tumor is obtained.

In a further embodiment of the present invention the large DEBs 81 and the small DEBs 82 are loaded with different drugs. For example, the tumor core 93 is typically hypoxic and so hypoxia-activated pro-drugs like TH-302 may have a greater efficacy in tumor kill, while traditional chemotherapy for the area of the tumor rim 92 could be used

where there is normoxia. As such, the tumor can be treated more effectively by targeting different parts of the tumor with different drugs. Potentially a better targeted dosage regime of large and small DEBs 81, 82 may result in a more precise drug dosage and therefore less side effects may be experienced by the patient. In an embodiment of the present invention the small DEBs 82 are loaded with hypoxia-activated pro-drugs like TH-302 and the large DEBs 82 are loaded with traditional chemotherapy drugs. The two (or more) chemotherapeutic drugs, may be used either in combination (first drug + second drug) or as a tumor micro-environment activated pro-drug (the first drug is activated in tumor microenvironment and promotes efficacy of the second drug). The first and second drug may have different concentrations. An alternative option is that the first drug and second drug are the same, but that the concentration is bead size specific. In all cases, other properties than the concentration (e.g. drug release rate) may be chosen to be different for different bead sizes.

In a further embodiment of the present invention the large DEBs 81 and the small DEBs 82 are loaded with different contrast agents. This facilitates imaging the large DEBs 81 and the small DEBs 82 separately with energy resolving imaging systems, such as spectral CT and k-edge imaging techniques. This avoids separation of the contrast agents from the DEBs 81,82 because the contrast agent is present within the bead. As such, it is possible to more accurately determine if the DEBs 81, 82 have reached their predetermined destination and if the vessels are properly embolized. When it is known how many of the DEBs actually reach the intended region of interest, a more precise dosage regime, e.g. lower doses and therefore less side effects, may be implemented.

Figure 4 depicts an exemplary, simulated CT reconstruction of a part of a patient's body including a liver 9. The liver 9 has a tumor, which comprises actual tumor mass containing tumor core vessels 93 and a blood supply area, which comprises at least one feeding vessel 91. Large DEBs 81 and small DEBs 82 were previously administered to the patient using injecting device 7. The liver 9 area was then imaged with a spectral CT imaging device 10. In this embodiment the large DEBs 81 were loaded with a different contrast agent (e.g. an Iodine based contrast agent) than the small DEBs 82 (e.g. a Gadolinium based contrast agent). Through k-edge imaging both contrast agents are individually identified and, as such, the location of the large DEBs 81 and the small DEBs 82 in the tumor area is known and can be depicted, for instance, by presenting this as an overlay over the CT image. In Figure 4 this is depicted as hatched areas for the location 93' of the small DEBs 83 and a 90 degrees tilted (compared to the small DEB area 93') hatched area for the location of the large

DEBs 81. A physician will immediately notice that the small DEBs 83 have penetrated into the tumor core, while the large DEBs 81 have penetrated the blood supply area.

Inherently radio-opaque DEBs provides direct visualization of bead deposition. This is a marked improvement in image-guided feedback. A degree of DEB radio-opacity is directly related to the drug dose. Multi-energy imaging, such as spectral CT, has the ability to image and quantitatively measure the DEB radio-opacity and thus the actual drug dose at the tumor site. A DEB concentration determiner 11 is configured to determine the drug concentration from obtained image data of the areas embolized by DEBs. This is of extremely high added value to TACE procedures. As mentioned previously, in TACE procedures it is actually very difficult to determine the drug dose that actually reaches the tumor. It is well known in chemotherapy medicine that a sufficient drug dose concentration is needed for tumor kill, but that many of the drugs unfortunately have severe side effects. Therefore it is crucial to find an optimal balance between sufficient drugs to treat the tumor, but not too much to severely discomfort an already weakened patient. With the elements of the present invention the drug dose at the tumor location and surrounding areas may be much more accurately and reliably determined. This will assist the physician to better determine an optimal dose and increase tumor treatment efficacy, while keeping side effects under control as much as possible, which increases the patient's quality of life during the treatment and because of that it might also improve treatment efficacy.

Figure 5A depicts a schematic flow chart of a TACE method comprising the steps of administering 101 first DEBs containing at least a first drug and a first contrast agent to a region of interest comprising a tumor, and administering 102 second DEBs containing at least a second drug and a second contrast agent to the region of interest, wherein the first DEBs have a larger diameter than the second DEBs. Preferably the first and second DEBs contain different drugs and/or contrast agents.

Figure 5B depicts a schematic flow chart of a method for determining a delivered drug dose concentration in a region of interest comprising a tumor, comprising the steps of obtaining 201 a first image data set by imaging the region of interest with an x-ray imager operating at a first x-ray radiation energy and determining 203, from the first image data set, a first drug concentration delivered to the region of interest by first DEBs containing at least a first drug and a first contrast agent, obtaining 202 a second image data set by imaging the region of interest with an x-ray imager operating at a second x-ray radiation energy and determining 204, from the second image data set, a second drug concentration

delivered to the region of interest by second DEBs containing at least a second drug and a second contrast agent, wherein the first DEBs have a larger diameter than the second DEBs.

An imaging system 1 arranged to obtain a first image data set of the region of interest with at least a first x-ray radiation energy and a second image data set of the region of interest with at least a second x-ray radiation energy, such as a CT imaging system or a cone-beam CT (CBCT) imaging system, is particularly suitable to determine concentrations. When a concentration of the first and second drugs are known for the region (or respective regions) of interest, this provides an excellent indication of the actually delivered drug dose to the region(s) of interest. A ratio of contrast to drug concentration for every bead size is necessary to determine the specific drug dose. In imaging systems which do not obtain image data at more than one energy level, e.g. MR imaging systems, it is possible to distinguish microspheres of different sizes that contain different contrast agents, but not to quantify the drug dose. After all, it is the chemotherapy drug (or drugs) and not the contrast medium having the tumoricidal effect. And also, the signal intensity from, for instance, MR imaging is in arbitrary units, whereas the multi-energy based imaging provides absolute measurement units of concentration. This is an inherent technical advantage of multi-energy imaging such as spectral CT or CBCT imaging. Therefore, this not only provides absolute measurement metrics, the TACE system of the present invention allows for inter-patient visualization and comparison of drug delivery, which is important for image guidance and follow-up and for assessing efficacy of treatment.

Preferably the x-ray imager operates at a first pair of x-ray energies to obtain the first image data set and at a second pair of x-ray energies to obtain the second data set, since this is a prerequisite for k-edge imaging of a contrast agent. Preferably the image data sets are reconstructed to visual data and displayed to a physician 205. The visual data may comprise the location of the differently sized DEBs and/or drug concentration at specific locations. This may be done by overlaying a CT image with additional information, such as hatched or colored areas, numerical data on or with the reconstructed CT image or any other suitable way of displaying visual data known in the art.

The present invention also relates to an imaging system that is configured to determine a drug concentration in a tumor after a TACE procedure. Said system comprises an imaging system 10, preferably a spectral CT imaging system that can obtain data sets of areas of interests that are embolized by at least two differently sized DEBs. These DEBs may contain different drugs and/or contrast agents. The system further comprises a concentration determiner 11 to determine the drug concentrations from the first and second image data sets

of each of the differently sized DEBs at a region of interest, such as a tumor area including feeding areas and the tumor core. Preferably the image data sets are reconstructed in a reconstructor to visual data that may be presented to a physician on a display unit. The visual data may comprise the location of the differently sized DEBs an/or drug concentration at specific locations. This may be done by overlaying a CT image with additional information, such as hatched or colored areas, numerical data on or with the CT image or any other suitable way of displaying visual data known in the art.

The present invention further relates to a computer program product for determining a drug concentration in a tumor after a transarterial chemoembolization (TACE) procedure in which at least a first drug and a second drug were delivered to the region of interest, comprising instructions to execute the steps of determining a first and a second drug concentration a first and second image data set of the region of interest when the computer program product is run on the computer. Preferably the first and second image data set were obtained at different x-ray radiation energies, such as with a spectral CT imaging device. Preferably the first and second drugs were delivered to the region of interest by at least two differently sized DEBs, preferably containing different drugs and/or contrast agents.

Figure 6 presents a schematic representation of a kit-of-parts 300 comprising a quantity 301 of first DEBs containing at least a first drug and a first contrast agent; and a quantity 302 of second DEBs containing at least a first drug and a first contrast agent. Preferably the first and second DEBs contain different drugs and/or contrast agents. Either of the first or second DEBs may be DOXDEBs. The first and second quantity of DEBs may be such that they are already provided in a desired quantity ratio. The first and second DEBs may be provided separately or as a pre-mixed mixture.

While the invention has been illustrated and described in detail in the drawings and foregoing description, such illustration and description are to be considered illustrative or exemplary and not restrictive; the invention is not limited to the disclosed embodiments.

Other variations to the disclosed embodiments can be understood and effected by those skilled in the art in practicing the claimed invention, from a study of the drawings, the disclosure, and the appended claims. In the claims, the word "comprising" does not exclude other elements or steps, and the indefinite article "a" or "an" does not exclude a plurality. A single processor or other unit may fulfill the functions of several items recited in the claims. The mere fact that certain measures are recited in mutually different dependent claims does not indicate that a combination of these measures cannot be used to advantage. A computer program may be stored/distributed on a suitable medium, such as an optical storage

medium or a solid-state medium supplied together with or as part of other hardware, but may also be distributed in other forms, such as via the Internet or other wired or wireless telecommunication systems. Any reference signs in the claims should not be construed as limiting the scope.

CLAIMS:

1. System (10) for a transarterial chemoembolization of a region of interest comprising a tumor, comprising:
 - an injecting device (7) arranged to introduce into the region of interest first drug-eluting microsphere beads (81) containing at least a first drug and a first contrast agent
 - 5 and to introduce into the region of interest second drug-eluting microsphere beads (82) containing at least a second drug and a second contrast agent;
 - an imaging system (1) arranged to obtain a first image data set of the region of interest with at least a first x-ray radiation energy and a second image data set of the region of interest with at least a second x-ray radiation energy; and
 - 10 - a concentration determiner (11) arranged to determine a first drug concentration from the first image data set and a second drug concentration from the second image data set.
2. System according to claims 1, wherein the imaging system (1) is a spectral
15 computed tomography imaging system, preferably a spectral computed tomography system that is arranged to simultaneously obtain the first image data and second image data.
3. System according to any of the claims 1-2, wherein the first drug-eluting
20 microsphere beads (81) have a size such that they can not penetrate into tumor core vessels (93), and the second drug-eluting microsphere beads (82) have a size such that they can penetrate into tumor core vessels (93).
4. System according to any of the claims 1-3, wherein the first drug is different
25 from the second drug and/or wherein the first contrast agent is different from the second contrast agent.
5. System according to any of the claims 1-4, wherein the at least first x-ray radiation energy corresponds to a K-absorption edge of the first contrast agent and the at least

second x-ray radiation energy corresponds to a K-absorption edge of the second contrast agent.

6. Method for determining a delivered drug dose concentration in a region of interest comprising a tumor, comprising the steps of:
- obtaining (201) a first image data set by imaging the region of interest with an x-ray imaging device (1) operating at at least a first x-ray radiation energy;
 - determining (203), from the first image data set, a first drug concentration delivered to the region of interest by first drug-eluting microsphere beads (81) containing at least a first drug and a first contrast agent;
 - obtaining (202) a second image data set by imaging the region of interest with an x-ray imaging device (1) operating at at least a second x-ray radiation energy;
 - determining (204), from the second image data set, a second drug concentration delivered to the region of interest by second drug-eluting microsphere beads (82) containing at least a second drug and a second contrast agent,
- wherein the first drug-eluting microsphere beads have a larger diameter than the second drug-eluting microsphere beads.
7. Method according to claim 6, wherein the first image data and the second image data are obtained simultaneously, preferably by spectral computed tomography.
8. Method according to any of the claims 6-7, wherein the first drug-eluting microsphere beads (81) have a size such that they can not penetrate into tumor core vessels (93), and the second drug-eluting microsphere beads (82) have a size such that can penetrate into tumor core vessels (93).
9. Method according to any of the claims 6-8, wherein the first drug is different from the second drug and/or wherein the first contrast agent is different from the second contrast agent.
10. Method according to claim 6-9, wherein the at least first x-ray radiation energy corresponds to a K-absorption edge of the first contrast agent and the at least second x-ray radiation energy corresponds to a K-absorption edge of the second contrast agent.

11. System for determining a drug concentration in a region of interest comprising a tumor after a transarterial chemoembolization procedure, comprising:
- an imaging system (1) arranged to:
 - obtain, at a first x-ray radiation energy, a first image data set of the region of interest comprising first drug-eluting microsphere beads (81) containing at least a first drug and a first contrast agent and/or second drug-eluting microsphere beads (82) containing at least a second drug and a second contrast agent; and
 - obtain, at a second x-ray radiation energy, a second image data set of the region of interest comprising first drug-eluting microsphere beads containing at least a first drug and a first contrast agent and/or second drug-eluting microsphere beads containing at least a second drug and a second contrast agent; and
 - a concentration determiner arranged to:
 - determine a first drug concentration and a second drug concentration from the first image data set; and
 - determine a first drug concentration and a second drug concentration from the second image data set.
12. Computer program product for determining a drug concentration in a tumor after a transarterial chemoembolization procedure in which at least a first drug and a second drug were delivered to the region of interest, comprising instructions to execute the steps of:
- determine a first drug concentration and a second drug concentration from a first image data set of the region of interest and from a second image data set of the region of interest; and
 - determine a first drug concentration and a second drug concentration from a first image data set of the region of interest and from a second image data set of the region of interest,
- when the computer program product is run on the computer.
13. Transarterial chemoembolization method comprising the steps of:
- administering (101) a first drug-eluting microsphere beads containing at least a first drug and a first contrast agent to a region of interest comprising a tumor,
 - administering (102) a second drug-eluting microsphere beads containing at least a second drug and a second contrast agent to the region of interest,

wherein the first drug-eluting microsphere beads have a larger diameter than the second drug-eluting microsphere beads.

14. Kit-of-parts (300) comprising:
- 5 - a quantity (301) of first drug-eluting microsphere beads containing at least a first drug and a first contrast agent; and
- a quantity (302) of second drug-eluting microsphere beads containing at least a first drug and a first contrast agent.

1/3




FIG. 1




FIG. 2

2/3




FIG. 3




FIG. 4

3/3




FIG. 5A






FIG. 5B



300




FIG. 6

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2015/078737

A. CLASSIFICATION OF SUBJECT MATTER INV. A61B6/00 A61B6/03 ADD. A61M5/00 A61K49/04		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) A61B A61M A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPO-Internal, WPI Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2010/007545 A1 (KONINKL PHILIPS ELECTRONICS NV [NL]; PHILIPS INTELLECTUAL PROPERTY [DE] 21 January 2010 (2010-01-21) page 3, line 15 - page 8, line 28 -----	1-12
X	US 2008/102029 A1 (FRITZ ULF [DE] ET AL) 1 May 2008 (2008-05-01)	13,14
Y	paragraph [0036] - paragraph [0041] paragraph [0053] - paragraph [0054] paragraph [0086] - paragraph [0087] paragraph [0095] - paragraph [0105] paragraph [0177] - paragraph [0201] -----	1-12
A	WO 2013/186661 A1 (KONINKL PHILIPS NV [NL]; PHILIPS DEUTSCHLAND GMBH [DE]) 19 December 2013 (2013-12-19) page 4, line 10 - page 12, line 10 ----- -/--	1-14
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents :		
<p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>		<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>
Date of the actual completion of the international search 12 May 2016		Date of mailing of the international search report 03/06/2016
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016		Authorized officer Hooper, Martin

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2015/078737

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2011/014562 A1 (UNIV NORTH CAROLINA STATE [US]; KLEINSTREUER CLEMENT [US]) 3 February 2011 (2011-02-03) page 15, line 29 - page 24, line 20 -----	1-14

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2015/078737

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2010007545	A1	21-01-2010	
		CN 102098963 A	15-06-2011
		EP 2303125 A1	06-04-2011
		JP 5539342 B2	02-07-2014
		JP 2011528248 A	17-11-2011
		US 2011097273 A1	28-04-2011
		WO 2010007545 A1	21-01-2010

US 2008102029	A1	01-05-2008	
		US 2008102029 A1	01-05-2008
		US 2015258224 A1	17-09-2015

WO 2013186661	A1	19-12-2013	
		CN 104379063 A	25-02-2015
		EP 2861147 A1	22-04-2015
		JP 2015525101 A	03-09-2015
		US 2015110346 A1	23-04-2015
		WO 2013186661 A1	19-12-2013

WO 2011014562	A1	03-02-2011	
		US 2012190976 A1	26-07-2012
		WO 2011014562 A1	03-02-2011
